Alexander Spira, MD, PhD | Authors


The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC

June 06, 2021

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

PACIFIC Regimen Is Appropriate for Use in Patients With Non–Small Cell Lung Cancer After Chemoradiation

April 17, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.

Amivantamab Plus Lazertinib Combo Shows Good Results in EGFR+ NSCLC

November 10, 2020

Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.